A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Lipase (Primary)
- Indications Exocrine pancreatic insufficiency; Pancreatitis
- Focus Adverse reactions
- Acronyms MS1819-SD
- 27 Sep 2017 Data from the first six treated patients presented in an AzurRx BioPharma Media Release.
- 23 Aug 2017 According to an AzurRx BioPharma media release, to further support enrollment in this trial and other planned future trials, company has added an additional clinical site in Australia.
- 23 Aug 2017 According to an AzurRx BioPharma media release, 6th patient has been enrolled and results from these first six patients are expected in September 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History